Adaptive Radiotherapy for Head and Neck Cancer: Implications for Clinical and Dosimetry Outcomes

被引:46
|
作者
Surucu, Murat [1 ]
Shah, Karan K. [1 ]
Roeske, John C. [1 ]
Choi, Mehee [1 ]
Small, William, Jr. [1 ]
Emami, Bahman [1 ]
机构
[1] Loyola Univ, Med Ctr, Dept Radiat Oncol, 2160 S 1st Ave, Maywood, IL 60153 USA
关键词
adaptive radiotherapy; head and neck cancer; IGRT; tumor volume reduction rate; intensity modulated radiotherapy; INTENSITY-MODULATED RADIOTHERAPY; VOLUME REDUCTION RATE; IMAGE-GUIDED IMRT; RADIATION-THERAPY; HELICAL TOMOTHERAPY; SHRINKAGE; IMPACT;
D O I
10.1177/1533034616662165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To investigate the effects of adaptive radiotherapy on dosimetric, clinical, and toxicity outcomes for patients with head and neck cancer undergoing chemoradiotherapy with intensity-modulated radiotherapy. Methods: Fifty-one patients with advanced head and neck cancer underwent definitive chemoradiotherapy with the original plan optimized to deliver 70.2 Gy. All patients were resimulated at a median dose of 37.8 Gy (range, 27.0-48.6 Gy) due to changes in tumor volume and/or patient weight loss (>15% from baseline). Thirty-four patients underwent adaptive replanning for their boost planning (21.6 Gy). The dosimetric effects of the adaptive plan were compared to the original plan and the original plan copied on rescan computed tomography. Acute and late toxicities and tumor local control were assessed. Gross tumor volume reduction rate was calculated. Results: With adaptive replanning, the maximum dose to the spinal cord, brain stem, mean ipsilateral, and contralateral parotid had a median reduction of -4.5%, -3.0%, -6.2%, and -2.5%, respectively (median of 34 patients). Median gross tumor volume and boost planning target volume coverage improved by 0.8% and 0.5%, respectively. With a median follow-up time of 17.6 months, median disease-free survival and overall survival was 14.8 and 21.1 months, respectively. Median tumor volume reduction rate was 35.2%. For patients with tumor volume reduction rate 35.2%, median disease-free survival was 8.7 months, whereas it was 16.9 months for tumor volume reduction rate >35.2%. Four patients had residual disease after chemoradiotherapy, whereas 64.7% (20 of 34) of patients achieved locoregional control. Conclusion: Implementation of adaptive radiotherapy in head and neck cancer offers benefits including improvement in tumor coverage and decrease in dose to organs at risk. The tumor volume reduction rate during treatment was significantly correlated with disease-free survival and overall survival.
引用
收藏
页码:218 / 223
页数:6
相关论文
共 50 条
  • [1] Clinical outcomes of adaptive radiotherapy in head and neck cancers
    Kataria, Tejinder
    Gupta, Deepak
    Goyal, Shikha
    Bisht, Shyam S.
    Basu, Trinanjan
    Abhishek, Ashu
    Narang, Kushal
    Banerjee, Susovan
    Nasreen, Shahida
    Sambasivam, Sasikumar
    Dhyani, Aruj
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1062):
  • [2] Brain dosimetry from locally advanced head and neck cancer radiotherapy: implications for neurocognitive outcomes research
    McDonald, Andrew M.
    Murdaugh, Donna L.
    Milner, Desmin
    Cardan, Rex A.
    Bhatia, Smita
    [J]. ACTA ONCOLOGICA, 2018, 57 (11) : 1589 - 1592
  • [3] A systematic review on clinical adaptive radiotherapy for head and neck cancer
    Lindegaard, Anne Marie
    Hakansson, Katrin
    Bernsdorf, Mogens
    Gothelf, Anita B.
    Kristensen, Claus A.
    Specht, Lena
    Vogelius, Ivan R.
    Friborg, Jeppe
    [J]. ACTA ONCOLOGICA, 2023, 62 (11) : 1360 - 1368
  • [4] Adaptive Radiotherapy of Head and Neck Cancer
    Castadot, Pierre
    Lee, John A.
    Geets, Xavier
    Gregoire, Vincent
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2010, 20 (02) : 84 - 93
  • [5] Adaptive Radiotherapy for Head Neck Cancer
    Mali S.B.
    [J]. Journal of Maxillofacial and Oral Surgery, 2016, 15 (4) : 549 - 554
  • [6] Adaptive radiotherapy for head and neck cancer
    Castelli, J.
    Simon, A.
    Lafond, C.
    Perichon, N.
    Rigaud, B.
    Chajon, E.
    De Bari, B.
    Ozsahin, M.
    Bourhis, J.
    de Crevoisier, R.
    [J]. ACTA ONCOLOGICA, 2018, 57 (10) : 1284 - 1292
  • [7] Adaptive Radiotherapy for Head-and-Neck Cancer: Initial Clinical Outcomes From a Prospective Trial
    Schwartz, David L.
    Garden, Adam S.
    Thomas, Jimmy
    Chen, Yipei
    Zhang, Yongbin
    Lewin, Jan
    Chambers, Mark S.
    Dong, Lei
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (03): : 986 - 993
  • [8] Dosimetry in vivo in radiotherapy of head and neck cancer patients
    Miszczyk, L
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 437 - 437
  • [9] Does adaptive radiotherapy for head and neck cancer favorably impact dosimetric, clinical, and toxicity outcomes?: A review
    Simopoulou, Foteini
    Kyrgias, George
    Georgakopoulos, Ioannis
    Avgousti, Rafaela
    Armpilia, Christina
    Skarlos, Pantelis
    Softa, Vasiliki
    Theodorou, Kiki
    Kouloulias, Vassilis
    Zygogianni, Anna
    [J]. MEDICINE, 2024, 103 (26)
  • [10] The use of in-vivo dosimetry to detect head and neck cancer patients needing adaptive radiotherapy
    Fiagan, Y. A. C.
    Nevens, D.
    Bossuyt, E.
    Machiels, M.
    Chiairi, I.
    Joye, I.
    Paul, M.
    Gevaert, T.
    Verellen, D.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1680 - S1681